Beyond Neuralink: Science Corp. Enters the Human Frontier

Max Hodak’s Science Corp. has confirmed its transition to human clinical trials, marking a pivotal moment in the competitive race for high-bandwidth brain-computer interfaces. By moving from preclinical models to human neuro-implantation, the firm is positioning itself as a primary challenger in the burgeoning field of neurological restoration.